Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRAS | P01112 | 12/20 | 0.87 |
| ▸ | FNTA | P49354 | 1/20 | 0.66 |
| ▸ | FNTB | P49356 | 1/20 | 0.66 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8499641 | 1.00 | HRAS (0.87) | HRASFNTAFNTBLTA4HMMP3 | |
| SCHEMBL7654412 | 0.94 | HRAS (0.78) | HRASFNTAFNTBMMP3 | |
| SCHEMBL7648622 | 0.93 | HRAS (1.00) | HRASFNTAFNTBLTA4H | |
| SCHEMBL6842134 | 0.93 | HRAS (1.00) | HRASFNTAFNTBLTA4H | |
| SCHEMBL7654209 | 0.91 | HRAS (0.95) | HRASFNTAFNTB | |
| SCHEMBL7655180 | 0.89 | HRAS (0.92) | HRASFNTAFNTBLTA4H | |
| SCHEMBL7653253 | 0.89 | HRAS (0.92) | HRASFNTAFNTB | |
| SCHEMBL7860387 | 0.89 | HRAS (0.92) | HRASFNTAFNTB | |
| SCHEMBL6810001 | 0.89 | HRAS (0.77) | HRASFNTAFNTBMMP3 | |
| SCHEMBL7860400 | 0.88 | HRAS (0.87) | HRASFNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6492410-B1 | SUCH AS 1-((4-BENZYLOXY-BENZYL)-((2-METHYL-2-PHENYL-PROPYL-CARBAMOYL)-METHYL) -CARBAMOYL)-2-(3H-IMIDAZOL-4-YL)-ETHYL)-CARB AMIC ACID BENZYL ESTER WITH LOVASTATIN OR ATORVASTATIN | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | claimed |
| US-6300501-B1 | Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase | WARNER-LAMBERT COMPANY | 2001-10-09 | — | — | US | claimed |
| EP-1077949-A2 | COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG COA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER | WARNER-LAMBERT COMPANY (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999058505-A2 | COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG COA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER | WARNER-LAMBERT COMPANY (US) | 1999-11-18 | — | — | WO | claimed |
| EP-0938494-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-09-01 | — | — | EP | claimed |
| WO-1997044350-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | claimed |
| US-6492410-B1 | SUCH AS 1-((4-BENZYLOXY-BENZYL)-((2-METHYL-2-PHENYL-PROPYL-CARBAMOYL)-METHYL) -CARBAMOYL)-2-(3H-IMIDAZOL-4-YL)-ETHYL)-CARB AMIC ACID BENZYL ESTER WITH LOVASTATIN OR ATORVASTATIN | WARNER-LAMBERT COMPANY | 2002-12-10 | — | — | US | disclosed |
| EP-1077949-A2 | COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG COA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER | WARNER-LAMBERT COMPANY (US) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058505-A2 | COMBINATIONS OF PROTEIN FARNESYLTRANSFERASE AND HMG COA REDUCTASE INHIBITORS AND THEIR USE TO TREAT CANCER | WARNER-LAMBERT COMPANY (US) | 1999-11-18 | — | — | WO | disclosed |
| EP-0938494-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1999-09-01 | — | — | EP | disclosed |
| WO-1997044350-A1 | INHIBITORS OF PROTEIN FARNESYL TRANSFERASE | WARNER-LAMBERT COMPANY (US) | 1997-11-27 | — | — | WO | disclosed |